Annual report pursuant to Section 13 and 15(d)

Intangible Assets

v3.19.2
Intangible Assets
12 Months Ended
Jun. 30, 2019
Intangible Assets  
Intangible Assets

7.    Intangible Assets

The Company has two categories of intangible assets – intellectual property and patents. Intellectual property consists of all technology, know-how, data, and protocols for producing targeted proteins in plants and related to any products and product formulations for pharmaceutical uses and for other applications. Intellectual property includes, but is not limited to, certain technology for the development and manufacture of novel vaccines and therapeutics for humans and certain veterinary applications acquired in December 2003 from Fraunhofer USA Inc., acting through its Center for Molecular Biotechnology ("Fraunhofer"), pursuant to a Technology Transfer Agreement, as amended (the "TTA"). The Company designates such technology further developed and acquired from Fraunhofer as iBioLaunch™ technology or as iBioModulator™ technology. The value on the Company’s books attributed to patents owned or controlled by the Company is based on payments for services and fees related to the protection of the Company’s patent portfolio. The intellectual property also includes certain trademarks.

In January 2014, the Company entered into a license agreement with a U.S. university whereby iBio acquired exclusive worldwide rights to certain issued and pending patents covering specific candidate products for the treatment of fibrosis (the "Licensed Technology"). The license agreement provides for payment by the Company of a license issue fee, annual license maintenance fees, reimbursement of prior patent costs incurred by the university, payment of a milestone payment upon regulatory approval for sale of a first product, and annual royalties on product sales. In addition, the Company has agreed to meet certain diligence milestones related to product development benchmarks. As part of its commitment to the diligence milestones, the Company successfully commenced production of a plant-made peptide comprising the Licensed Technology before March 31, 2014. The next milestone – filing a New Drug Application with the FDA or foreign equivalent covering the Licensed Technology ("IND") – initially became due on December 1, 2015, and on August 11, 2016, the agreement was amended and subsequent six-month extensions have been automatically granted extending the due date until December 31, 2017, at which time, the Company and the university agreed to set a new milestone schedule and are currently undergoing an analysis based on new data and revised forecasted timelines.

The Company accounts for intangible assets at their historical cost and records amortization utilizing the straight-line method based upon their estimated useful lives. Patents are amortized over a period of 10 years and other intellectual property is amortized over a period from 16 to 23 years. The Company reviews the carrying value of its intangible assets for impairment whenever events or changes in business circumstances indicate the carrying amount of such assets may not be fully recoverable. Evaluating for impairment requires judgment, and recoverability is assessed by comparing the projected undiscounted net cash flows of the assets over the remaining useful life to the carrying amount. Impairments, if any, are based on the excess of the carrying amount over the fair value of the assets. There were no impairment charges during 2019 and 2018.

The following table summarizes by category the gross carrying value and accumulated amortization of intangible assets (in thousands):

 

 

 

 

 

 

 

 

 

    

June 30, 

    

June 30, 

 

 

2019

 

2018

Intellectual property – gross carrying value

 

$

3,100

 

$

3,100

Patents – gross carrying value

 

 

2,560

 

 

2,484

 

 

 

5,660

 

 

5,584

Intellectual property – accumulated amortization

 

 

(2,399)

 

 

(2,243)

Patents – accumulated amortization

 

 

(1,887)

 

 

(1,721)

 

 

 

(4,286)

 

 

(3,964)

Net intangible assets

 

$

1,374

 

$

1,620

 

Amortization expense, included in general and administrative expenses, was approximately $322,000 and $341,000 for 2019 and 2018, respectively. The weighted-average remaining life for intellectual property and patents at June 30, 2019 was approximately 4.5 years and 6.3 years, respectively. The estimated annual amortization expense for the next five years and thereafter is as follows (in thousands):

 

 

 

 

 

For the Year Ending

    

 

 

June 30, 

 

 

 

2020

 

$

294

2021

 

 

273

2022

 

 

260

2023

 

 

245

2024

 

 

149

Thereafter

 

 

153

Total

 

$

1,374